Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Short-term Investments (2016 - 2018)

Cumberland Pharmaceuticals (CPIX) has disclosed Short-term Investments for 7 consecutive years, with $8.3 million as the latest value for Q4 2018.

  • Quarterly Short-term Investments rose 77.44% to $8.3 million in Q4 2018 from the year-ago period, while the trailing twelve-month figure was $8.3 million through Dec 2018, up 77.44% year-over-year, with the annual reading at $8.3 million for FY2018, 77.44% up from the prior year.
  • Short-term Investments hit $8.3 million in Q4 2018 for Cumberland Pharmaceuticals, up from $4.7 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $15.6 million in Q4 2016 to a low of $4.7 million in Q4 2017.
  • Historically, Short-term Investments has averaged $11.6 million across 5 years, with a median of $14.6 million in 2015.
  • Biggest five-year swings in Short-term Investments: plummeted 70.09% in 2017 and later soared 77.44% in 2018.
  • Year by year, Short-term Investments stood at $14.8 million in 2014, then decreased by 1.87% to $14.6 million in 2015, then rose by 7.26% to $15.6 million in 2016, then tumbled by 70.09% to $4.7 million in 2017, then soared by 77.44% to $8.3 million in 2018.
  • Business Quant data shows Short-term Investments for CPIX at $8.3 million in Q4 2018, $4.7 million in Q4 2017, and $15.6 million in Q4 2016.